Over the past twelve months, ACB has reported earnings growth of 142.1%, putting it ahead of 90.87% of US stocks in our set.
The volatility of Aurora Cannabis Inc's share price is greater than that of 90.96% US stocks with at least 200 days of trading history.
Aurora Cannabis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -43.31%, greater than the shareholder yield of just 6.36% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Aurora Cannabis Inc are IPI, MD, HMTV, BBCP, and SND.
Aurora Cannabis Inc. Common Shares (ACB) Company Bio
Aurora Cannabis, Inc. is engaged in the production and distribution of medical cannabis. The company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. Its purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in 18 countries worldwide. It was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Vancouver, Canada.
Aurora Cannabis (ACB) investors are a resilient lot. The Canadian cannabis producer is notorious for diluting its shares via cash raising efforts. The company has continually burnt a hole through its reserves, and the share count has ballooned over the years as it has attempted to put the fires out. Its latest move has involved another attempt to pad the coffers; On Thursday, the company announced a bought deal of $125 million, in which it has agreed to sell approximately 12 million units for $10.45 each. Within a 30-day period, the underwriters can also buy an additional 10% of the units.
Back in September, I said Aurora Cannabis (NYSE:ACB) stock finally started to look like a risk worth taking. Since that time, ACB stock is up 63.9%. Source: Shutterstock Aurora shares have nearly tripled since Nov. 1 based on optimism about the path to U.S. federal legalization. But even if the U.S. eventually legalizes cannabis, Aurora will still be at a competitive disadvantage to better-positioned companies. Aurora still has major financial problems. The company recently completed its latest in a string of dilutive capital raised to fund its growth efforts. With the stock up big since Election Day, ACB stock investors should at least be taking some of those profits off the table at this point.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reasons to Like ACB Stock Des...
Shares of Canadian cannabis grower Aurora Cannabis (NYSE: ACB) dropped today after the company announced a new share offering. Aurora announced that it will be issuing 12 million new shares, plus additional warrants to purchase shares. Aurora will use the $125 million in proceeds "for general corporate purposes, which may include opportunistically reducing debt."
Aurora Cannabis (NYSE: ACB) announced yesterday that it has raised $125 million by issuing 12 million units priced at $10.45 each through a financing strategy called a "bought deal." The units are one share of the marijuana grower's stock and one half of a share's purchase warrant that can be exercised anytime over the next three years to acquire a full share of stock at a price of $12.60 per warrant share. BMO Capital Markets and ATB Capital Markets will be acquiring the units and have another 30 days to acquire an additional 10% of the total at the same terms if there is an overallotment.
Aurora Cannabis Inc.'s $125 million bought-deal financing is not surprising, but may not be enough for the Canadian company to establish a needed foothold in the U.S., Jefferies analyst Owen Bennett said Friday. "Following ACB's recent business update and restructured credit facility, we flagged a risk of underinvestment," Bennett wrote in a note to clients. Since that update, "US political developments also mean the US market could open up sooner rather than later. ACB will certainly need cash to establish a US foothold, yet we still wonder if this is enough. Further, a strong US presence is arguably required to support the current multiple," the analyst wrote. Jefferies rates Aurora as underperform with a $3.58 stock price target. The company announced the capital raise late Thursday ...